AzTrials
AzTrials

STIGIFTNCT05723484

Comparing a Novel Point-of-care Cytokine Biomarker Lateral Flow Test With Nucleic Acid Amplification Tests for Detection of Sexually Transmitted Infections and Bacterial Vaginosis

An observational study of STI, run by University of Cape Town at 3 sites in 3 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

1. To evaluate the performance of a lateral flow POC test, namely the Genital InFlammation Test (GIFT), for identifying women with inflammatory STIs and BV, who are at higher risk of HIV infection and reproductive complications; 2. Read more about this study

Who is it for?
Ages 18 to 35 years, women only
Conditions the study is for
STI
What is being tested?
GIFT Device
Type of treatment
Medical device
How many people
675 participants
Where
3 sitesin 3 countries
Study dates
1 Jun 2023to 31 Dec 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • Women only
  • Adult

Study population: Diagnostic: Non-pregnant, sexually active women aged 18-35 years accessing family planning services. Integration: * Local or regional policy makers: maximum 36 * Healthcare professionals: maximum 40 * Pregnant and non-pregnant, sexually active women of 18-35 years attending family planning services: maximum 45 * Pregnant and non-pregnant, sexually active women of 18-35 years attending family planning services: up to 200 participants per site for discrete choice experiment * Data from pregnant and non-pregnant, sexually active women of 18-35 years attending family planning services recruited in diagnostic study * Healthcare workers from diagnostic study sites

Diagnostic Inclusion Criteria:

  • 18-35 years old
  • Willing and able to provide informed consent to participate in the study
  • Self-reported to be sexually active
  • Not pregnant (determined by pregnancy test)
  • Accessing family planning service

Integration Inclusion Criteria:

For all: Willing and able to provide informed consent to participate in the study

User experiences/perceptions activity:

  • Local or regional policy makers, programmers and other opinion leaders and decision makers
  • Healthcare professionals at health facilities
  • Women who are eligible for the diagnostic study (including pregnant and menstruating women), but who are not part of the diagnostic study
  • 18-35 years old
  • Willing and able to provide informed consent to participate in the study
  • Self-reported to be sexually active
  • Accessing family planning service diagnostic study

Discrete choice experiments:

  • Women who are eligible for the diagnostic study (including pregnant and menstruating women), who are either part of, or not part of, the diagnostic study
  • 18-35 years old
  • Self-reported to be sexually active
  • Accessing family planning service diagnostic study

Decision tree classification algorithm:

  • Data from diagnostic study participants

Economic evaluation:

  • Healthcare professionals at health facilities involved in GIFT device implementation able to complete timesheets

Diagnostic Exclusion Criteria:

  • <18 years or >35 years
  • Refusal by a participant to participate in the study
  • Treatment for any STI/BV in the past 30 days
  • Pregnancy
  • Enrolled in a study which does not allow co-enrolment in other studies

Integration Exclusion Criteria:

For all: Not willing or able to provide informed consent to participate in the study

User experiences/perceptions activity:

  • Non-relevant policy makers
  • Healthcare professionals at health facilities not included in diagnostic study

Women who are:

  • Part of the diagnostic study
  • <18 years or >35 years
  • Treated for any STI/BV in the past 30 days
  • Pregnant
  • Enrolled in a study which does not allow co-enrolment in other studies

Discrete choice experiments:

Women who are:

  • <18 years or >35 years
  • Treated for any STI/BV in the past 30 days
  • Pregnant
  • Enrolled in a study which does not allow co-enrolment in other studies

Decision tree classification algorithm:

  • Participants for whom there are no diagnostic study data

Economic evaluation:

  • Healthcare professionals not at study sites, not involved in GIFT device implementation, and/or not able to complete timesheets

Trial locations and contacts

3 sites in 3 countries.

3 sites in 3 countries

Madagascar1 site
  • Centre Hospitalier Universitaire Gynéco-Obstétrique de Befelatanana

    Antananarivo

Other trials in Madagascar

South Africa1 site
  • Desmond Tutu Health Foundation

    Cape Town, Western Cape, 7975

Other trials in South Africa

Zimbabwe1 site
  • Chitungwiza Primary Health Care Clinics

    Harare

Other trials in Zimbabwe

About this study

Official title: A Multi-centre Diagnostic Study to Evaluate the Feasibility and Performance of the Genital InFlammation Test (GIFT)

  1. To evaluate the performance of a lateral flow POC test, namely the Genital InFlammation Test (GIFT), for identifying women with inflammatory STIs and BV, who are at higher risk of HIV infection and reproductive complications;
  2. To evaluate how the GIFT device can be integrated in a feasible, acceptable, and cost-effective way into routine care.
Read the detailed description

DIAGNOSTIC Study

Design:

The study is a multicentre, multidisciplinary, cross sectional, prospective clinically based research project.

The first component is a diagnostic study which will enrol 225 women attending family planning services in each of the three study sites in South Africa, Zimbabwe, and Madagascar. Vaginal samples from the women will be applied to the GIFT device and results will be compared with the composite NAAT reference test for STIs and Nugent score test for BV to determine the performance of the device to detect STIs/BV. Women will attend only one study visit but will be recalled for treatment if required.

The second component to develop a feasible, acceptable and economically feasible STI/BV management algorithm which includes the use of the GIFT device to be integrated into national guidelines (hereafter referred to as the "integration study") is composed of four activities with different study designs: 1.User experiences and/or perceptions of the GIFT device involving qualitative focus group discussions and in-depth interviews, and a quantitative questionnaire for health care professionals; 2. Discrete choice experiment; 3 Development of a decision tree classification algorithm; 4. Economic evaluation of the defined management algorithms.

Study Sites:

  1. Cape Town, South Africa; Desmond Tutu Health Foundation (DTHF) Masiphumelele
  2. Harare, Zimbabwe; Chitungwiza Primary Health Care Clinics
  3. Antananarivo, Madagascar; Centre Hospitalier Universitaire Gynéco-Obstétrique de Befelatanana

Diagnostic Device:

The GIFT device is an immune-based lateral flow test for reproductive-aged, non-pregnant in resource-limited settings attending sexual reproductive health (family planning) clinics, community health centers, hospitals, and mobile clinics. The test involves the qualitative detection of genital inflammation caused by asymptomatic STIs and BV in self- or clinician-collected lateral vaginal wall swabs, with results available in less than 20 minutes.

Diagnostic Study Objectives:

Primary objectives To assess the sensitivity and specificity of the GIFT device at the point-of-care in non-pregnant sexually active women aged 18-35 years accessing family planning services in South Africa, Zimbabwe, and Madagascar.

Secondary objectives To assess the predictive values of the GIFT device at the point-of-care in non-pregnant sexually active women aged 18-35 years accessing family planning services in South Africa, Zimbabwe, and Madagascar; To assess the performance of the GIFT device at the point-of-care in non-pregnant sexually active women aged 18-35 years accessing family planning services in each of the countries; To assess the performance of the device versus syndromic management without any laboratory testing (standard of care in South Africa, Zimbabwe, and Madagascar); To determine the robustness of the device by comparing results read by clinicians with those read by laboratory professionals, and with the results obtained using an automated reader; To evaluate the accuracy of the GIFT device by comparing the GIFT device results with ELISA (enzyme-linked immunosorbent assay) results using previously validated concentration cut-offs as the gold standard, including validation of the GIFT cytokine concentration cut-offs for each cytokine biomarker.

Exploratory objectives Determine if other determinants (such as intermediate microbiota (Nugent 4-6), age, parity, sexual activity) improve the prediction of STI/BV status in women; To use 16S rRNA gene sequencing and vaginal bacteria specific quantitative NAATs to evaluate the proportion of cases of genital inflammation explained by vaginal dysbiosis that was not diagnosed as an STI or BV by NAATs or Nugent scoring; To explore the performance of the device in the presence of vaginal Candida spp colonisation.

INTEGRATION Study To evaluate how the GIFT device can be integrated in a feasible, acceptable, and cost-effective way into routine care (the "integration study"), four activities will be conducted: 1. User experiences and/or perceptions of the GIFT device; 2. Discrete choice experiment; 3 Development of a decision tree classification algorithm; 4. Economic evaluation of the defined management algorithms.

Objectives:

Primary objective To evaluate how the GIFT device could be integrated into routine care.

Secondary objectives To qualitatively and quantitatively assess the user-experience, usability, and acceptability of the GIFT device at the point of care; To examine patient preferences for various STI management aspects (attributes) to inform the development of STI management algorithms that integrate the GIFT device; To generate algorithms that integrate the GIFT device to optimise case finding and STIs/vaginal infection management in women, using the complete dataset from the study; To determine the cost and budget impact of the identified screening or diagnostic algorithm with the GIFT device, and to model the cost- effectiveness of different strategies of integration of GIFT into care.

Conditions
STI
Being tested
GIFT Device
Medical subject headings
Sexually Transmitted Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • GIFT DeviceDevice

    The GIFT device - immune-based lateral flow test for reproductive-aged, non-pregnant in resource-limited settings attending sexual reproductive health (family planning) clinics, community health centers, hospitals, and mobile clinics. The test involves the qualitative detection of genital inflammation caused by asymptomatic STIs and BV in self- or clinician-collected lateral vaginal wall swabs, with results available in less than 20 minutes.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Estimates of sensitivity and specificity for the GIFT device

    Detecting the presence of any STI or BV with 95% confidence intervals, using NAATs and Nugent scoring in a composite reference standard.

    Measured: Start- quarter 1/2023; End- quarter 4/2023

  2. How the GIFT device could be integrated into routine care

    Integration into healthcare guidelines

    Measured: Start- quarter 1/2023; End- quarter 4/2023

Secondary outcomes (10)
  1. Positive and negative predictive values of the GIFT device

    predictive values of the GIFT device in each country and likelihood ratios, using NAATs and Nugent scoring as a composite reference standard

    Measured: Start- quarter 1/2023; End- quarter 4/2023

  2. Overall sensitivity of NAAT and Nugent scoring

    Specificity and predictive values in each country using NAATs and Nugent scoring

    Measured: Start- quarter 1/2023; End- quarter 4/2023

  3. Overall sensitivity

    Specificity and predictive values in each country and likelihood ratios of syndromic management, using NAATs and Nugent scoring as composite reference standards

    Measured: Start- quarter 1/2023; End- quarter 4/2023

  4. Comparison of sensitivity, specificity, predictive values in each country and likelihood ratios calculated with both methods

    GIFT device and syndromic management using NAATs and Nugent scoring as composite reference standards

    Measured: Start- quarter 1/2023; End- quarter 4/2023

  5. Positive and negative agreement proportion and Kappa coefficient between results readings of 1/clinician and technician

    2/clinician and automated reader; 3/technician and automated reader

    Measured: Start- quarter 1/2023; End- quarter 4/2023

  6. Positive and negative agreement proportion and Kappa coefficient between results readings of GIFT device and cytokine ELISA measurements

    GIFT device and cytokine ELISA measurements

    Measured: Start- quarter 1/2023; End- quarter 4/2023

  7. User experiences

    Perceptions of GIFT device

    Measured: Start- quarter 1/2023; End- quarter 4/2023

  8. User preferences

    different STI management strategies based on patient preferences for various attributes of STI management using GIFT device

    Measured: Start- quarter 2/2023; End- quarter 1/2024

  9. Optimal case finding and STI management strategies

    Using diagnostic study results

    Measured: Start: - quarter 1/2024; End- quarter 4/2024

  10. Cost and budget impact

    Economic evaluation for the budget impact analysis to create strategies of integrating the GIFT device into standard of care

    Measured: Start- quarter 3/2023; End- quarter 2/2024

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Feb 2023
  2. Study start1 Jun 2023
  3. Primary completion31 Dec 2023
  4. Study completion31 Dec 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
675 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05723484
Sponsor's protocol ID
GIFT_EDCTP-RIA2020I-3297
Acronym
GIFT
Status last verified
Aug 2025
First submitted
27 Jan 2023
Last updated
6 Aug 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: De-identified study data will be made available to the study team only.

Publications

  • Ramboarina S, Crucitti T, Gill K, Bekker LG, Harding-Esch EM, van de Wijgert JHHM, Huynh BT, Fortas C, Harimanana A, Mayouya Gamana T, Randremanana RV, Mangahasimbola R, Dziva Chikwari C, Kranzer K, Mackworth-Young CRS, Bernays S, Thomas N, Anderson D, Tanko FR, Manhanzva M, Lurie M, Khumalo F, Sinanovic E, Honda A, Pidwell T, Francis SC, Masson L, Passmore JA; GIFT study group. Novel point-of-care cytokine biomarker lateral flow test for the screening for sexually transmitted infections and bacterial vaginosis: study protocol of a multicentre multidisciplinary prospective observational clinical study to evaluate the performance and feasibility of the Genital InFlammation Test (GIFT). BMJ Open. 2024 May 1;14(5):e084918. doi: 10.1136/bmjopen-2024-084918.

    PubMed 38692732

Questions about this trial

What is this clinical trial studying?

An observational study of STI, run by University of Cape Town at 3 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Madagascar, South Africa, Zimbabwe. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Estimates of sensitivity and specificity for the GIFT device (time frame: Start- quarter 1/2023; End- quarter 4/2023). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05723484, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in